Clinical trial
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
NCT00103935 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00103935 |
|---|---|
| Title | Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes |
| Official title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Pharmacokinetics of Exenatide Long-Acting Release Administered Weekly in Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | placebo, Exenatide LAR |
| Enrollment | 45 |
| Start date | Feb 1, 2005 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Feb 18, 2005 |
| Last update posted | Feb 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: